Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848700 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT05848700: Completed Phase 1 study of Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT05848700 is a Phase 1 study of Schizophrenia that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 60 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05848700, a Phase 1 study of Schizophrenia, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States. It will be accepting male and female participants age 18 years to 65 years. Participation will be up to approximately10 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SEP-363856
Study Locations (7)
Arkansas
- Woodland International Research Group, LLC - Little Rock
- Woodland Research Northwest - Rogers
Florida
- Behavioral Clinical Research, Inc - Miami Lakes
- Research Centers of America at Fort Lauderdale Behavioral Health Center - Oakland Park
Georgia
- Atlanta Center for Medical Research - Atlanta
Ohio
- Neuro-Behavioral Clinical Research, Inc - North Canton
Texas
- Pillar Clinical Research, LLC - Richardson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2024-03-15 |
| Phase | Phase 1 |
What the finished NCT05848700 record still lists
NCT05848700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05848700 lists 7 locations in 5 states (Arkansas, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT05848700 about?
NCT05848700 is a clinical study titled "A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia". A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States. It will be accepting male and female participants age 18 years to 65 years. Participation will be up to approximately10 weeks.
What is the current status of trial NCT05848700?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-06-21. Estimated completion is 2024-03-15.
What conditions does trial NCT05848700 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT05848700?
The interventions under investigation include: Placebo (DRUG), SEP-363856 (DRUG).
Who is sponsoring clinical trial NCT05848700?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05848700 being conducted?
This trial has 7 study locations across Arkansas, Florida, Georgia, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05848700's enrollment target sits among peer trials
60 188th of 315 higher than 119 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI